Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Linagliptin as add-on therapy for type 2 diabetes - an overview.

Brown DX, Choudhury M, Evans M.

Drugs Today (Barc). 2012 Oct;48(10):645-54. doi: 10.1358/dot.2012.48.10.1860771. Review.

PMID:
23110260
2.

Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.

Grunberger G.

Postgrad Med. 2013 May;125(3):79-90. doi: 10.3810/pgm.2013.05.2663. Review.

PMID:
23748509
3.

Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.

Ghatak SB, Patel DS, Shanker N, Srivastava A, Deshpande SS, Panchal SJ.

Curr Diabetes Rev. 2011 Sep;7(5):325-35. Review.

PMID:
21916836
4.

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

Derosa G, Maffioli P.

Diabetes Technol Ther. 2012 Apr;14(4):350-64. doi: 10.1089/dia.2011.0204. Epub 2012 Feb 10. Review.

PMID:
22324384
5.

Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.

Barnett AH.

Adv Ther. 2011 Jun;28(6):447-59. doi: 10.1007/s12325-011-0028-y. Epub 2011 May 17. Review.

PMID:
21603986
6.

DPP-4 inhibitors: what may be the clinical differentiators?

Gerich J.

Diabetes Res Clin Pract. 2010 Nov;90(2):131-40. doi: 10.1016/j.diabres.2010.07.006. Epub 2010 Aug 13. Review.

PMID:
20708812
7.

Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Toth PP.

Postgrad Med. 2011 Jul;123(4):46-53. doi: 10.3810/pgm.2011.07.2303. Review.

PMID:
21680988
8.

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.

von Websky K, Reichetzeder C, Hocher B.

Vasc Health Risk Manag. 2013;9:681-94. doi: 10.2147/VHRM.S40035. Epub 2013 Nov 1. Review.

9.

Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.

Kalra S, Unnikrishnan AG, Agrawal N, Singh AK.

Recent Pat Endocr Metab Immune Drug Discov. 2011 Sep;5(3):197-202.

PMID:
21913883
10.

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Golightly LK, Drayna CC, McDermott MT.

Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.2165/11632930-000000000-00000. Review. Erratum in: Clin Pharmacokinet. 2012 Dec;51(12):831.

PMID:
22686547
11.

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.

Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K.

Drug Des Devel Ther. 2013 Sep 17;7:989-1001. doi: 10.2147/DDDT.S37647. eCollection 2013. Review.

12.

Linagliptin: an update of its use in patients with type 2 diabetes mellitus.

McKeage K.

Drugs. 2014 Oct;74(16):1927-46. doi: 10.1007/s40265-014-0308-3. Review.

PMID:
25297911
13.

[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].

Scheen AJ, Van Gaal LF.

Rev Med Liege. 2012 Feb;67(2):91-7. French.

14.

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.

Deacon CF, Holst JJ.

Expert Opin Investig Drugs. 2010 Jan;19(1):133-40. doi: 10.1517/13543780903463862. Review.

PMID:
19947894
15.

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Scheen AJ.

Clin Pharmacokinet. 2010 Sep;49(9):573-88. doi: 10.2165/11532980-000000000-00000. Review.

PMID:
20690781
16.

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1561-76. doi: 10.1517/17425255.2011.628986. Epub 2011 Oct 25. Review.

PMID:
22022857
17.

Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.

Aletti R, Cheng-Lai A.

Cardiol Rev. 2012 Jan-Feb;20(1):45-51. doi: 10.1097/CRD.0b013e31823a3afc. Review.

PMID:
22143285
18.

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.

Forst T, Pfützner A.

Expert Opin Pharmacother. 2012 Jan;13(1):101-10. doi: 10.1517/14656566.2012.642863. Review.

PMID:
22149370
19.

Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.

Takai S, Sakonjo H, Jin D.

J Pharmacol Sci. 2014;125(4):386-93. Epub 2014 Jul 17.

20.

Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.

Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M.

Am J Kidney Dis. 2015 Sep;66(3):441-9. doi: 10.1053/j.ajkd.2015.03.024. Epub 2015 May 7.

Supplemental Content

Support Center